Advertisement
Advertisement
VNRX
VolitionRx Limited
0.77
USDSponsored
-0.01
-1.07%
Aug 10, 15:59 UTC -4
Closed
After-Market
0.77
+0.01
+0.65%
VNRX Earnings Reports
Positive Surprise Ratio
VNRX beat 24 of 42 last estimates.
57%
Next Report
Date of Next Report
Aug 19, 2026
Estimate for Q2 26 (Revenue/ EPS)
$492.32K
/-$0.58
Implied change from Q1 26 (Revenue/ EPS)
-50.02%
/-40.21%
Implied change from Q2 25 (Revenue/ EPS)
+20.96%
/-51.67%
VolitionRx Limited earnings per share and revenue
On May 14, 2026, VNRX reported earnings of -0.97 USD per share (EPS) for Q1 26, missing the estimate of -0.73 USD, resulting in a -32.08% surprise. Revenue reached 985.00 thousand, compared to an expected 435.13 thousand, with a 126.37% difference. The market reacted with a -9.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 6 analysts forecast an EPS of -0.58 USD, with revenue projected to reach 492.32 thousand USD, implying an decrease of -40.21% EPS, and decrease of -50.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
TELA Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.20
Surprise
-10.01%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Septerna, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.43
Actual
-$0.28
Surprise
+33.26%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Sana Biotechnology, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+12.58%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were VolitionRx Limited's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, VolitionRx Limited reported EPS of -$0.97, missing estimates by -32.08%, and revenue of $985.00K, 126.37% above expectations.
How did the market react to VolitionRx Limited's Q1 2026 earnings?
The stock price moved down -9.09%, changed from $2.20 before the earnings release to $2.00 the day after.
When is VolitionRx Limited expected to report next?
The next earning report is scheduled for Aug 19, 2026.
What are the forecasts for VolitionRx Limited's next earnings report?
Based on 6
analysts, VolitionRx Limited is expected to report EPS of -$0.58 and revenue of $492.32K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement